ArticleBMC pediatrics2026
Association and predictive value of blood branched-chain and excitatory amino acids with autism spectrum disorder severity.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAutism spectrum disorder (ASD) is a neurodevelopmental disorder with heterogeneous severity. Abnormal amino acid metabolism may contribute to ASD pathogenesis, but the relationship between amino acid levels and severity remains unclear. This study investigated the association and predictive value of blood amino acid profiles for ASD severity.
methodsWe enrolled 474 children with ASD, divided into mild-to-moderate (CARS 30-36, n = 123) and severe groups (CARS 37-60, n = 351). Tandem mass spectrometry measured blood branched-chain amino acids (BCAAs) and excitatory amino acids (EAAs). Multivariate logistic and restricted cubic spline regressions analyzed associations and dose-response relationships. Model performance was evaluated by ROC, calibration, and decision curve analysis.
resultsThe severe group had higher total BCAAs (307.50 ± 79.94 vs. 284.74 ± 70.51 µmol/L, P = 0.005) and EAAs (245.18 ± 72.02 vs. 227.83 ± 67.32 µmol/L, P = 0.020). After full adjustment, leucine/isoleucine showed the strongest association with severe ASD (OR = 1.012, 95% CI: 1.006-1.018, P < 0.001), followed by glutamate (OR = 1.005, 95% CI: 1.002-1.009, P = 0.006). BCAAs, leucine/isoleucine, and EAAs exhibited linear positive correlations with severe ASD risk; glutamate showed nonlinear association. Leucine/isoleucine had optimal predictive performance (AUC = 0.807, 95% CI: 0.765-0.849; sensitivity 69.80%, specificity 76.42% at 125.595 µmol/L). Subgroup analysis indicated that the associations between amino acids and ASD severity were stronger in children ≤ 3 years old and those with low BMI, with valine showing an interaction with sex (P = 0.045).
conclusionsBlood BCAAs and EAAs were closely associated with ASD severity, with leucine/isoleucine as the strongest predictor. Amino acid profile-based models provide biomarker evidence for identifying severe ASD and precision intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.